News - Merck & Co, MK-3475

Filter

Current filters:

Merck & CoMK-3475

Popular Filters

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

Merck starts roll-out of BLA for MK-3475; vorapaxar FDA panel review

14-01-2014

US drug giant Merck & Co says it has started a rolling submission to the US Food and Drug Administration…

Cardio-vascularMerck & CoMK-3475North AmericaOncologyPharmaceuticalRegulationUSAvorapaxarZontivity

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

Merck & Co trialing MK-3475 with GSK’s pazopanib in renal cancer

18-12-2013

US pharma giant Merck & Co says it has initiated a clinical trial to evaluate the combination of the…

GlaxoSmithKlineMerck & CoMK-3475OncologyPazopanib TabletsPharmaceuticalResearch

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

19-11-2013

US pharma giant Merck & Co has announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy,…

Merck & CoMK-3475OncologyPharmaceuticalResearch

Back to top